<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: The Patentability of Enantiomers - Implications for the Pharmaceutical Industry</title>
	<atom:link href="http://stlr.stanford.edu/2007/02/the-patentability-of-enantiomers/feed/" rel="self" type="application/rss+xml" />
	<link>http://stlr.stanford.edu/2007/02/the-patentability-of-enantiomers/</link>
	<description></description>
	<lastBuildDate>Tue, 14 May 2013 13:38:46 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Clare</title>
		<link>http://stlr.stanford.edu/2007/02/the-patentability-of-enantiomers/comment-page-1/#comment-61</link>
		<dc:creator>Clare</dc:creator>
		<pubDate>Sat, 19 Jan 2008 03:31:40 +0000</pubDate>
		<guid isPermaLink="false">http://www.stanford.edu/group/stlr/cgi-bin/wp/?p=235#comment-61</guid>
		<description>If I understand correctly, and there is a case to be made for non-renewal of certain pharmaceutical patents, then the general public is the potential winner. It would open up the possibilty that large numbers of patented drugs could be released for conversion to generic forms.</description>
		<content:encoded><![CDATA[<p>If I understand correctly, and there is a case to be made for non-renewal of certain pharmaceutical patents, then the general public is the potential winner. It would open up the possibilty that large numbers of patented drugs could be released for conversion to generic forms.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
